Practical Consensus Guidelines for the Use of S-1 in GI Malignancies

Area of Science:

• Oncology
• Pharmacology

Background:

• S-1, a combination of 5-fluorouracil prodrug (tegafur) with CDHP and potassium oxonate (OXO), was approved in 1999.
• Gastrointestinal (GI) malignancies represent a significant area of cancer research and treatment.

Purpose of the Study:

• To establish expert consensus guidelines for the practical application of S-1 in GI cancers.
• To optimize the use of S-1 in patients with colorectal, gastric, and pancreatic tumors.

Main Methods:

• A modified Delphi method was employed, involving 15 subject matter experts over six months.
• Experts discussed, analyzed, and voted on 17 key aspects of S-1 utilization in GI oncology.

Main Results:

• A majority consensus was achieved for all 17 key points, with approval ratings from 87% to 100%.
• S-1's efficacy and reduced toxicity profile are supported by clinical data and meta-analyses.
• S-1 is recommended as a standard of care for all lines of therapy in colorectal and pancreatic cancers.

Conclusions:

• S-1 is a well-established standard of care for GI cancers, including colorectal and pancreatic malignancies.
• S-1 in combination with oxaliplatin is the standard of care for gastric cancer treatment.